These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 1582975

  • 1. Mechanisms of bone lesions in multiple myeloma.
    Bataille R, Chappard D, Klein B.
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):285-95. PubMed ID: 1582975
    [Abstract] [Full Text] [Related]

  • 2. The mechanisms of bone lesions in human plasmacytomas.
    Bataille R.
    Stem Cells; 1995 Aug; 13 Suppl 2():40-7. PubMed ID: 8520510
    [Abstract] [Full Text] [Related]

  • 3. [Mechanisms for formation of myeloma bone disease].
    Yata K, Abe M, Matsumoto T.
    Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
    [Abstract] [Full Text] [Related]

  • 4. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.
    Zannettino AC, Farrugia AN, To LB, Atkins GJ.
    Methods Mol Med; 2005 Apr; 113():245-56. PubMed ID: 15968108
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
    Torcia M, Lucibello M, Vannier E, Fabiani S, Miliani A, Guidi G, Spada O, Dower SK, Sims JE, Shaw AR, Dinarello CA, Garaci E, Cozzolino F.
    Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
    [Abstract] [Full Text] [Related]

  • 7. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma.
    Bataille R, Chappard D, Klein B.
    Int J Clin Lab Res; 1992 Jul; 21(4):283-7. PubMed ID: 1591381
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N, Colla S, Rizzoli V.
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Bone disease in multiple myeloma and its mechanism].
    Abe M.
    Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA, Higgins LS.
    Exp Cell Res; 2006 Jun 10; 312(10):1909-23. PubMed ID: 16600214
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pathogenesis of myeloma bone disease.
    Roodman GD.
    Blood Cells Mol Dis; 2004 Jun 10; 32(2):290-2. PubMed ID: 15003820
    [Abstract] [Full Text] [Related]

  • 20. Evidence for the secretion of an osteoclast stimulating factor in myeloma.
    Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE.
    N Engl J Med; 1974 Nov 14; 291(20):1041-6. PubMed ID: 4413338
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.